60 Degrees Pharmaceuticals Inc (SXTP) Quote

continued buying down to .21, then took some profit up towards .40 and buying back on the pullback since then, but didnt trade as well as I would have liked, leaving me now with about 40K with lifetime cost around .24, not bad, but I really want to see this take off. At this point would do some selling in the mid-30s. This could be a real winner

Five immuno compromised patients cured of Babesioses given off label by doctors -this is getting interesting

40% of Lyme disease patients have Babesia https://danielcameronmd.com/babesia-and-lyme-its-worse-than-you-think/

Recruitment of at least 24 hospitalized patients diagnosed with babesiosis will begin after a site initiation visit at Tufts Medical Center on June 13, 2024.

Babesiosis is a steadily emerging, infectious disease transmitted by a microscopic parasite, Babesia, through the bite of the black-legged (deer) tick, the vector that spreads Lyme disease. Babesiosis, an orphan disease, may be life-threatening in elderly and immunosuppressed patients. Up to 10 percent of Lyme disease patients may be coinfected with Babesia. Therefore, up to 47,600 of the estimated 476,000 patients with new Lyme infections each year may be coinfected with Babesia.

“With tick-borne illnesses on the rise in the U.S., babesiosis is rapidly emerging as a condition of serious clinical concern,” said Dr. Geoff Dow, chief executive officer at 60 Degrees Pharmaceuticals. “The literature suggests tafenoquine may be a promising alternative for the treatment of patients hospitalized with relapsing babesiosis, so we are pleased to partner with Tufts Medical Center to conduct the first clinical trial of tafenoquine in treating hospitalized babesiosis patients. The results may eventually lead to an expanded indication for tafenoquine that will address this growing public health concern.”

Tufts Medical Center is one of several prominent university hospitals planning to participate in the study. 60 Degrees Pharmaceuticals is in negotiations with other leading university hospitals in the Northeast U.S. to add two other clinical trial sites.

Tafenoquine is approved for malaria prophylaxis in the United States under the product name ARAKODA®. The safety of the approved regimen of tafenoquine for malaria prophylaxis has been assessed in five separate randomized, double-blind, active comparator or placebo-controlled trials for durations of up to six months. Tafenoquine has not been proven to be effective for treatment or prevention of babesiosis and is not approved by the U.S. Food and Drug Administration for such an indication.

About the Study of Tafenoquine for Patients Hospitalized with Babesiosis

The study is a randomized, double-blind, placebo-controlled trial that will enroll patients at multiple sites in the Northeast U.S. and will compare the safety and efficacy of tafenoquine versus placebo in patients hospitalized for babesiosis. The two main study endpoints will be the time to sustained clinical resolution of symptoms and the time to molecular cure as determined by an FDA-approved nucleic acid test (NAT). At least 24, and as many as 33 patients, will be recruited before an interim analysis is conducted. Sufficient enrollment capacity is planned to allow all study subjects to be recruited during the 2024 tick season (June to September) if caseload is high. The interim analysis will include both a test of significance, as well as size re-estimation to allow additional recruitment if required. The study will be conducted at three hospitals in the Northeast U.S. The efficacy and safety of 8-aminoquinolines, a class of drugs that includes tafenoquine and primaquine, for prevention and treatment of malaria is well documented. Several case reports of tafenoquine use for babesiosis indicate that the drug is already being used for this purpose in the practice of medicine in the U.S.

About ARAKODA® (tafenoquine)
Tafenoquine was discovered by Walter Reed Army Institute of Research. Tafenoquine was approved for malaria prophylaxis in 2018 in the United States as ARAKODA® and in Australia as KODATEF®. Both were commercially launched in 2019 and are currently distributed through pharmaceutical wholesaler networks in each respective country. They are available at retail pharmacies as a prescription-only malaria prevention drug. According to the Centers for Disease Control and Prevention, the long terminal half-life of tafenoquine, which is approximately 16 days, may offer potential advantages in less-frequent dosing for prophylaxis for malaria. ARAKODA is not suitable for everyone, and patients and prescribers should review the Important Safety Information below. Individuals at risk of contracting malaria are prescribed ARAKODA 2 x 100 mg tablets once per day for three days (the loading phase) prior to travel to an area of the world where malaria is endemic, 2 x 100 mg tablets weekly for up to six months during travel, then 2 x 100 mg in the week following travel.

ARAKODA® (tafenoquine) Important Safety Information
ARAKODA® is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older.

Contraindications
ARAKODA® should not be administered to:

Glucose-6-phosphate dehydrogenase (“G6PD”) deficiency or unknown G6PD status;
Breastfeeding by a lactating woman when the infant is found to be G6PD deficient or if
G6PD status is unknown;
Patients with a history of psychotic disorders or current psychotic symptoms; or
Known hypersensitivity reactions to tafenoquine, other 8-aminoquinolines, or any component of ARAKODA®.
Warnings and Precautions
Hemolytic Anemia: G6PD testing must be performed before prescribing ARAKODA® due to the risk of hemolytic anemia. Monitor patients for signs or symptoms of hemolysis.
G6PD Deficiency in Pregnancy or Lactation: ARAKODA® may cause fetal harm when administered to a pregnant woman with a G6PD-deficient fetus. ARAKODA® is not recommended during pregnancy. A G6PD-deficient infant may be at risk for hemolytic anemia from exposure to ARAKODA® through breast milk. Check infant’s G6PD status before breastfeeding begins.
Methemoglobinemia: Asymptomatic elevations in blood methemoglobin have been observed. Initiate appropriate therapy if signs or symptoms of methemoglobinemia occur.
Psychiatric Effects: Serious psychotic adverse reactions have been observed in patients with a history of psychosis or schizophrenia, at doses different from the approved dose. If psychotic symptoms (hallucinations, delusions, or grossly disorganized thinking or behavior) occur, consider discontinuation of ARAKODA® therapy and evaluation by a mental health professional as soon as possible.
Hypersensitivity Reactions: Serious hypersensitivity reactions have been observed with administration of ARAKODA®. If hypersensitivity reactions occur, institute appropriate therapy.
Delayed Adverse Reactions: Due to the long half-life of ARAKODA® (approximately 17 days), psychiatric effects, hemolytic anemia, methemoglobinemia, and hypersensitivity reactions may be delayed in onset and/or duration.
Adverse Reactions: The most common adverse reactions (incidence greater than or equal to 1 percent) were: headache, dizziness, back pain, diarrhea, nausea, vomiting, increased alanine aminotransferase (ALT), motion sickness, insomnia, depression, abnormal dreams, and anxiety.
Drug Interactions
Avoid co-administration with drugs that are substrates of organic cation transporter-2 (OCT2) or multidrug and toxin extrusion (MATE) transporters.

Use in Specific Populations
Lactation: Advise women not to breastfeed a G6PD-deficient infant or infant with unknown G6PD status during treatment and for 3 months after the last dose of ARAKODA®.
To report SUSPECTED ADVERSE REACTIONS, contact 60 Degrees Pharmaceuticals, Inc. at 1- 888-834-0225 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. The full prescribing information of ARAKODA® is located here.

About 60 Degrees Pharmaceuticals, Inc.

https://stockcharts.com/h-sc/ui?s=SXTP&p=D&yr=0&mn=5&dy=10&id=p24986097784&listNum=23&a=1113701411

https://stockcharts.com/h-sc/ui?s=sxtp&p=W&yr=1&mn=6&dy=0&id=p24986097784&listNum=23&a=1113701411

need .29 break

https://stockcharts.com/h-sc/ui?s=SXTP&p=D&yr=0&mn=5&dy=10&id=p24986097784&listNum=23&a=1113701411

wants eod push

goal is to see 1 here and buy .AZTR before the run

now everyone wants the next big dick LUCY. building consistent volume as volume increased on friday

thanks, nevermind the fuckface seller at .34 jee sell before the big breakout. this an AZTR here

thanks, nevermind the fuckface seller at .34 jee sell before the big breakout. this an AZTR here

Oh yeah? Good

biotech frenzy next

https://stockcharts.com/h-sc/ui?s=sxtp&p=30&yr=0&mn=0&dy=15&id=p24986097784&listNum=23&a=1113701411

https://stockcharts.com/h-sc/ui?s=sxtp&p=W&yr=1&mn=6&dy=0&id=p24986097784&listNum=23&a=1113701411

https://stockcharts.com/h-sc/ui?s=SXTP&p=D&yr=0&mn=5&dy=10&id=p24986097784&listNum=23&a=1113701411

Fyi link for stocks under 25 cents
https://marketxls.com/screener/333/penny-stocks-under-25-cents
Next day settlement begins May 28

loaded at .31

SXTP under 25 cents

Continued to buy as it has stairstepped down now at 25K shares. I definitely expect a nice run at one point and will take profits appropriately though I dont have a specific plan in place yet, I would look to start selling in the .40s, also dependent on what the news is.

I'd like to wring the neck of management for what they did. Luckily I took some profits in the .80s, only to see it drop to .30 and below where I have picked up a little and would buy more at .29. At this price it should be safely priced. When it spikes back up I dont know.

60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering

Taken on new position in SXTP on this downdraft. This is more of a shorter term trade looking for it to go back over a buck, lets see.

WHO is the idiot trying to sell 78K shares @ $1.09 ALL AT ONCE ??? Break UP that sell order genius....Are you TRYING to create a wall / stop a run?

$SXTP
https://x.com/hannahadad8890/status/1739964080163541132?s=61

https://finviz.com/quote.ashx?t=SXTP&p=d
https://dilutiontracker.com/app/search/SXTP

Absolutely agree..

Has a “thinking about buying” promoters dumping on all 3 right now,once they done,if they don’t destroy it and enough ppl see potential it might go up,has to have excellent financials and astronomical potential for continuation

Wild

Don’t mess with algo’s

Half the float is traded and this about to go red

$SXTP
https://x.com/hannahadad8890/status/1737839683814768844?s=61

Algo’s once again ruining a ticker. The spread was as high as .12 yesterday

What a market

$SXTP 19.9% 13Ghttps://t.co/2TGdN884FX pic.twitter.com/5Lizh4wZKG— STOCKS Gambino (@StocksGambino) December 18, 2023

INSCRUTABLE DUMPING

INDESCRIBABLE DUMPING

60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria

Not when they dilute unlimited

SXTP News Low Float Recent IPO no resistance above 2.50$

$SXTP - 👆Up 13.7% Pre-Market/ Current Price $2.43
Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects

All your predictions are wrong on every board. No one believes anything you post.

Wow. Down to $2.01 yesterday. -- We'll have to wait for the 10Q to see what type of scam they're pulling.

I don't see that happening anytime in the near future.

SXTP, a garbage and scam, that's why everybody is shorting it. Dead Cat!

i think tomorrow will be a good day..only a darn fool would short it here. solid volume and base. i say it runs hard am pre ..we shall see

Patience always pay off

Here goes

maybe if folks dont scalp every 2 cent... thats what happens when the confidence in the game is not what it use to be